Evidence map›Paper›PMID 33115662›Full record

ArticleJournal of biotechnology2021

PTSelect™: A post-transcriptional technology that enables rapid establishment of stable CHO cell lines and surveillance of clonal variation.

Vandhana Muralidharan-Chari, Zachary Wurz, Francis Doyle, Matthew Henry, Andreas Diendorfer, Scott A Tenenbaum, Nicole Borth, Edward Eveleth, Susan T Sharfstein

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Screening Strategies for High-Yield Chinese Hamster Ovary Cell Clones.Frontiers in bioengineering and biotechnology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Vandhana Muralidharan-ChariCollege of Nanoscale Science and Engineering, SUNY Polytechnic Institute, Albany, NY, New York 12203, USA.
Zachary WurzHocusLocus, LLC, 253 Fuller Road, Albany NY 12203, USA.
Francis DoyleCollege of Nanoscale Science and Engineering, SUNY Polytechnic Institute, Albany, NY, New York 12203, USA.
Matthew HenryAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, St. Lucia, QLD, 4072, Australia.
Andreas DiendorferAustrian Centre of Industrial Biotechnology, Graz, Austria, University of Natural Resources and Life Sciences, Vienna, Austria.
Scott A TenenbaumCollege of Nanoscale Science and Engineering, SUNY Polytechnic Institute, Albany, NY, New York 12203, USA.
Nicole BorthAustrian Centre of Industrial Biotechnology, Graz, Austria, University of Natural Resources and Life Sciences, Vienna, Austria.
Edward EvelethHocusLocus, LLC, 253 Fuller Road, Albany NY 12203, USA.
Susan T SharfsteinCollege of Nanoscale Science and Engineering, SUNY Polytechnic Institute, Albany, NY, New York 12203, USA. Electronic address: ssharfstein@sunypoly.edu.
SUNY Polytechnic Institute · USAustrian Centre of Industrial Biotechnology (Austria) · ATHocuslocus (United States) · USThe University of Queensland · AU

Funding

Development of a Structurally Interacting RNA (sxRNA) technologyR01GM125870 · NIGMS · SUNY POLYTECHNIC INSTITUTE · PI TENENBAUM, SCOTT A · 2018 to 2021
$2.6M
Improvements to Biopharmaceutical ManufacturingR42GM114935 · NIGMS · HOCUSLOCUS, INC. · PI SHARFSTEIN, SUSAN T · 2017 to 2018
$1.4M
NIGMS NIH HHS R01 GM125870NIGMS NIH HHS R42 GM114935
6 · The paper itself

Abstract

Currently, stable Chinese hamster ovary cell lines producing therapeutic, recombinant proteins are established either by antibiotic and/or metabolic selection. Here, we report a novel technology, PTSelect™ that utilizes an siRNA cloned upstream of the gene of interest (GOI) that is processed to produce functional PTSelect™-siRNAs, which enable cell enrichment. Cells with stably integrated GOI are selected and separated from cells without GOI by transfecting CD4/siRNA mRNA regulated by PTSelect™-siRNAs and exploiting the variable expression of CD4 on the cell surface. This study describes the PTSelect™ principle and compares the productivity, doubling time and stability of clones developed by PTSelect™ with conventionally developed clones. PTSelect™ rapidly established a pool population with comparable stability and productivity to pools generated by traditional methods and can further be used to easily monitor productivity changes due to clonal drift, identifying individual cells with reduced productivity.

Indexed as

Antibodies, MonoclonalTechnologyAnimalsCHO CellsCricetinaeCricetulusRecombinant ProteinsAntibodies, MonoclonalRecombinant ProteinsCell enrichmentChinese hamster ovary cellsClonal variationMonoclonal antibodiesRecombinant protein productionSilencing RNA

Identifiers

PMID33115662
PMCPMC8995049
OpenAlexW3093912969

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.